or said another way, by the time exclusivity ends, vascepa should have such scale volume in terms of supply, it is unlikely that generics would be able to even compete on price. while v could lose market share due to new entrants, it seems less likely they would lose market share on price alone...
I think this situation is closer to the Premarin situation. Will generics be able to secure supply,refining, and still be cost competitive after lawsuits. The Amarin story is unique in my experience and in a good way!
Market Data 
Markets 
AI
